Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)

Background: Vedolizumab, a humanized antibody targeting the α4β7 integrin, was proven to be effective in the treatment of moderate-to-severe ulcerative colitis (UC) in randomized clinical trials. The aim of the POLONEZ study is to determine the demographic and clinical characteristics of the patient...

Full description

Bibliographic Details

Published in:	Therapeutic advances in gastroenterology Vol. 14; p. 17562848211036456
Main Authors:	Cichoż-Lach, Halina, Michalak, Agata, Kopertowska-Majchrzak, Maria, Eder, Piotr, Stawczyk-Eder, Kamila, Waszak, Katarzyna, Talar-Wojnarowska, Renata, Zatorski, Hubert, Solarska-Półchłopek, Anna, Chmielnicki, Jarosław, Filip, Rafał, Pękala, Anna, Janiak, Maria, Skrobot, Krzysztof, Kasińska, Ewa, Krogulecki, Michał, Królikowski, Piotr, Kłopocka, Maria, Liebert, Ariel, Poniewierka, Elżbieta, Smoła, Izabela, Gąsiorowska, Anita, Kaczka, Aleksandra, Wypych, Joanna, Wojciechowski, Krzysztof, Drygała, Szymon, Zagórowicz, Edyta
Format:	Journal Article
Language:	English
Published:	London, England SAGE Publications 2021 Sage Publications Ltd SAGE Publishing
Subjects:	Gastroenterology Inflammatory bowel disease Monoclonal antibodies Original Research Poland vedolizumab clinical practice ulcerative colitis National Drug Program
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!